Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 651 across all filing types
Latest filing 2021-04-27 Major Shareholding Noti…
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
[기재정정]주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on the Status of Large Shareholdings' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea for entities or individuals who acquire 5% or more of a company's shares. It details the shareholding structure, changes in ownership, and contractual agreements (such as pledges or loans) related to those shares. Since this document does not fit into specific categories like 'Director's Dealing' (which is for individual insider trades) or 'Annual Report', and it is a formal regulatory disclosure required by the Capital Markets Act, it falls under the 'Major Shareholding Notification' category.
2021-04-27 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding status, changes in ownership, and contractual relationships (pledges, loans) of major shareholders and their special relations. This falls under the category of Major Shareholding Notification.
2021-04-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. This type of filing is a mandatory disclosure by insiders (directors, officers, or major shareholders) regarding changes in their shareholdings. In the provided taxonomy, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives, including major shareholders.
2021-04-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form required by the Financial Supervisory Service (FSS) in South Korea when company insiders (directors, executives, or major shareholders) change their shareholdings. This falls under the category of 'Director's Dealing' (DIRS) as it reports personal share transactions by company executives.
2021-04-23 Korean
투자판단관련주요경영사항(알츠하이머병 치료제로서 GV 1001의 국내 제3상 임상시험계획 반려)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure from GemVax regarding the rejection of a Phase 3 clinical trial application for their Alzheimer's drug, GV1001, by the Ministry of Food and Drug Safety. This is a specific regulatory announcement concerning clinical trial status and legal/regulatory outcomes, which fits best under the 'Regulatory Filings' (RNS) category as it is a material event disclosure that does not fit into the more specific categories like M&A, dividends, or financial reports.
2021-04-22 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement approval, director/auditor compensation limits, and board composition. This matches the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes at general meetings.
2021-03-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.